Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin) - Poll - MDSpire

Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)

  • By

  • Emma Guttman-Yassky

  • Alan D. Irvine

  • Melinda Gooderham

  • Stephan Weidinger

  • Lynda Spelman

  • Jonathan I. Silverberg

  • Heidi Crane

  • Hany ElMaraghy

  • Louise DeLuca-Carter

  • Maria Lucia Buziqui Piruzeli

  • Georgia Martimianaki

  • Evangeline Pierce

  • Helena Agell

  • Diamant Thaçi

  • June 19, 2026

  • 0 min

Share

Original Source(s)

Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)

  • by Emma Guttman-Yassky, Alan D. Irvine, Melinda Gooderham, Stephan Weidinger, Lynda Spelman, Jonathan I. Silverberg, Heidi Crane, Hany ElMaraghy, Louise DeLuca-Carter, Maria Lucia Buziqui Piruzeli, Georgia Martimianaki, Evangeline Pierce, Helena Agell, Diamant Thaçi

  • June 19, 2026

Related Content

Allergen Sensitization in Skin of Color

Scoping review links contact allergy to AD severity

Association of the inflammatory marker suPAR with chronic pruritus of unknown origin – data from the SOMA.PRU study

Informatics-Based Psychotherapeutic and Psychiatric Interventions in Dermatology: Scoping Review of Impacts on Skin Disease Severity and Mental Health Outcomes